Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;58(7):928-36.
doi: 10.1093/cid/ciu012. Epub 2014 Jan 6.

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries

Andrew Hill  1 , Saye Khoo, Joe Fortunak, Bryony Simmons, Nathan Ford
Affiliations

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries

Andrew Hill et al. Clin Infect Dis. 2014 Apr.

Abstract

Background: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries.

Methods: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures.

Results: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir.

Conclusions: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.

Keywords: daclatasvir; faldaprevir; ribavirin; simeprevir; sofosbuvir.

PubMed Disclaimer

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. - PubMed
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 cause of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. - PMC - PubMed
    1. Razavi H, Estes C, Pasini K, Gower E, Hindman S. HCV treatment rate in select European countries in 2004–2010. J Hepatol. 2013;58(suppl 1):S22–3.
    1. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327–9. - PubMed
    1. World Health Organization. HIV/AIDS fact sheet. Updated October 2013. Available at: http://www.who.int/hiv/en/ Accessed 8 November 2013.

MeSH terms